Evidence map›Paper›PMID 33322711›Full record

ArticleInternational journal of molecular sciences2020

Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients.

Bozena Smolkova, Zuzana Cierna, Katarina Kalavska, Svetlana Miklikova, Jana Plava, Gabriel Minarik, Tatiana Sedlackova, Dana Cholujova, Paulina Gronesova, Marina Cihova and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Bozena SmolkovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.ORCID 0000-0002-4906-5652
Zuzana CiernaDepartment of Pathology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia.
Katarina Kalavska2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
Svetlana MiklikovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.ORCID 0000-0003-0692-1858
Jana PlavaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.ORCID 0000-0002-9356-6219
Gabriel MinarikDepartment of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovicova 6, 842 15 Bratislava, Slovakia.
Tatiana SedlackovaComenius University Science Park, Ilkovicova 8, 841 04 Bratislava, Slovakia.
Dana CholujovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
Paulina GronesovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
Marina CihovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
Karolina MajerovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
Marian KarabaDepartment of Oncosurgery, National Cancer Institute, Klenova 1, 83310 Bratislava, Slovakia.
Juraj BencaDepartment of Oncosurgery, National Cancer Institute, Klenova 1, 83310 Bratislava, Slovakia.
Daniel PindakDepartment of Oncosurgery, National Cancer Institute, Klenova 1, 83310 Bratislava, Slovakia.
Jozef Mardiak2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
Michal Mego2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.ORCID 0000-0002-6511-6827
Slovak Academy of Sciences · SKComenius University Bratislava · SKGeneton (Slovakia) · SKSlovak Medical University · SKUniversity of Trnava · SKVysoká Škola Zdravotníctva a Sociálnej Práce sv. Alžbety · SK

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-16-0010Agentúra na Podporu Výskumu a Vývoja APVV-16-0178ERA-NET EuroNanoMed II INNOCENTVedecká Grantová Agentúra MŠVVaŠ SR a SAV 1/0044/15Vedecká Grantová Agentúra MŠVVaŠ SR a SAV 1/0271/17Vedecká Grantová Agentúra MŠVVaŠ SR a SAV 1/0724/11Vedecká Grantová Agentúra MŠVVaŠ SR a SAV 2/0052/18
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) and the immune infiltration of tumors are closely related to clinical outcomes. This study aimed to verify the influence of stromal lymphocyte infiltration and the immune context of tumor microenvironment on the hematogenous spread and prognosis of 282 chemotherapy naïve primary BC patients. To detect the presence of mesenchymal CTCs, RNA extracted from CD45-depleted peripheral blood was interrogated for the expression of mesenchymal gene transcripts. Tumor-infiltrating lymphocytes (TILs) were detected in the stromal areas by immunohistochemistry, using CD3, CD8, and CD45RO antibodies. The concentrations of 51 plasma cytokines were measured by multiplex bead arrays. TILs infiltration in mesenchymal CTC-positive patients significantly decreased their progression-free survival (HR = 4.88, 95% CI 2.30-10.37,

Indexed as

BreastBreast NeoplasmsCD3 ComplexCD8 AntigensChemokine CCL7CytokinesDisease ProgressionFemaleHumansImmunohistochemistryInterleukin-15Leukocyte Common AntigensLymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm StagingNeoplastic Cells, CirculatingCD3 ComplexCD8 AntigensChemokine CCL7CytokinesInterleukin-15Leukocyte Common AntigensTGFB3 protein, humanTransforming Growth Factor beta3circulating tumor cellscytokinesprimary breast cancertumor-infiltrating lymphocytes

Identifiers

PMID33322711
PMCPMC7763628
OpenAlexW3112623469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.